Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

First Corlopam Renal Program study completed

Feb. 6, 1997

Cell migration inhibitors from Teijin

Feb. 6, 1997

Nortran completes trials in volunteers with antiarrhythmic

Feb. 5, 1997

Tanabe synthesizes ET antagonists

Feb. 5, 1997

AHP claims smooth muscle cell proliferation inhibitors

Feb. 4, 1997

Mylan Laboratories receives FDA approval for generic formulation

Jan. 30, 1997

FDA Cardiovascular and Renal Drugs Advisory Committee to meet February 27-28

Jan. 29, 1997

New use for established antianginal agent

Jan. 29, 1997

Korean investigators isolate natural antioxidant

Jan. 28, 1997

Novel myocardial protectant described by Taiwanese researchers

Jan. 28, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...